# A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

> **NCT04879329** · PHASE2 · RECRUITING · sponsor: **Seagen, a wholly owned subsidiary of Pfizer** · enrollment: 372 (estimated)

## Conditions studied

- Urothelial Carcinoma

## Interventions

- **DRUG:** disitamab vedotin
- **DRUG:** pembrolizumab

## Key facts

- **NCT ID:** NCT04879329
- **Lead sponsor:** Seagen, a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-05-03
- **Primary completion:** 2026-12-11
- **Final completion:** 2029-04-14
- **Target enrollment:** 372 (ESTIMATED)
- **Last updated:** 2026-04-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04879329

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04879329, "A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04879329. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*